Updated NETs Clinical Trials

1. PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2

   Condition:   Neuroendocrine Tumors
   Interventions:   Drug: One injection of 68Ga-NODAGA-E[c(RGDyK)]2;   Device: PET/CT
   Sponsor:   Rigshospitalet, Denmark
   Recruiting

2. Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

   Conditions:   Neuroendocrine Carcinoma;   Large Cell Neuroendocrine Carcinoma of the Lung;   High Grade Neuroendocrine Carcinoma, Any Site
   Intervention:   Drug: Pembrolizumab
   Sponsors:   Ochsner Health System;   Merck Sharp & Dohme Corp.
   Recruiting

3. PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

   Condition:   Prostate Cancer
   Intervention:   Drug: Avelumab
   Sponsor:   Andrew J. Armstrong, MD
   Recruiting

4. Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

   Conditions:   VHL Pancreatic Neuroendocrine Tumors;   Von Hippel-Lindau Disease;   Neuroendocrine Tumors
   Intervention:   Drug: 68-Gallium DOTATATE
   Sponsor:   National Cancer Institute (NCI)
   Recruiting

5. Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

   Condition:   Neuroendocrine Tumors
   Intervention:   Drug: 177Lu-DOTATOC
   Sponsors:   University of Warmia and Mazury;   Maria Sklodowska-Curie Institute - Oncology Center;   The Medical University of Warsaw; Poland;   The Diagnostic and Therapeutic Center Gammed; Poland;   National Center for Research and Development, Poland
   Recruiting

6. A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

   Condition:   Neuroendocrine Tumors
   Intervention:   Drug: ABI-009
   Sponsors:   Robert Ramirez;   Aadi, LLC
   Recruiting

7. Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

   Condition:   High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
   Interventions:   Drug: Pembrolizumab;   Drug: Irinotecan;   Drug: Paclitaxel
   Sponsors:   University of California, San Francisco;   Merck Sharp & Dohme Corp.
   Recruiting

8. Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

   Conditions:   Neuroendocrine Tumors;   Neuroendocrine Neoplasm of Lung
   Interventions:   Drug: Durvalumab;   Drug: Tremelimumab
   Sponsor:   Grupo Espanol de Tumores Neuroendocrinos
   Recruiting

9. Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

   Condition:   Neuroendocrine Carcinoma
   Interventions:   Drug: FOLFOXIRI Protocol;   Drug: Cisplatin injection
   Sponsors:   Federation Francophone de Cancerologie Digestive;   National Cancer Institute, France
   Not yet recruiting

10. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

    Conditions:   Neuroendocrine Tumor, Malignant;   Liver Metastases
    Interventions:   Device: Bland Embolization;   Combination Product: Transarterial chemoembolization;   Combination Product: Drug Eluting Beads Embolization
    Sponsors:   University of Pennsylvania;   Guerbet
    Recruiting

11. Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

    Conditions:   Advanced Digestive System Neuroendocrine Neoplasm;   Digestive System Neuroendocrine Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Neoplasm;   Midgut Neuroendocrine Tumor G1;   Pancreatic Neuroendocrine Tumor;   Refractory Digestive System Neuroendocrine Neoplasm
    Intervention:   Drug: Abemaciclib
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   Eli Lilly and Company
    Recruiting

12. Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

    Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

13. Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors

    Condition:   Neuroendocrine Tumors
    Interventions:   Diagnostic Test: Gallium-68 NODAGA-LM3 PET/CT;   Diagnostic Test: Gallium-68 DOTA-LM3 PET/CT;   Diagnostic Test: Gallium-68 DOTATATE PET/CT
    Sponsor:   Peking Union Medical College Hospital
    Recruiting

14. Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression

    Condition:   Neuroendocrine Tumors
    Interventions:   Drug: 90Y-DOTATATE;   Drug: (177Lu-DOTAOTyr3)Octreotate;   Drug: 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
    Sponsors:   University of Warmia and Mazury;   Stowarzyszenie Pacjentów i Osób Wspierających Chorych na Guzy Neuroendokrynne
    Recruiting

15. Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

    Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

16. Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

    Condition:   Neuroendocrine Tumors
    Intervention:   Drug: Satoreotide tetraxetan
    Sponsor:   Ipsen
    Recruiting

17. Dosimetry Guided PRRT With 177Lu-DOTATATE in Children

    Conditions:   Neuroendocrine Tumors;   Neuroblastoma;   Pheochromocytoma;   Paraganglioma
    Interventions:   Drug: 177Lu-DOTA-tyr3-OCTREOTATE;   Procedure: Peptide Receptor Radiotherapy (PRRT)
    Sponsors:   Sue O'Dorisio;   Advanced Accelerator Applications
    Not yet recruiting

18. Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

    Condition:   Gastro-enteropancreatic Neuroendocrine Tumor
    Interventions:   Drug: Lutathera;   Drug: long-acting octreotide;   Drug: high dose long-acting octreotide
    Sponsor:   Advanced Accelerator Applications
    Recruiting

19. Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

    Conditions:   Gastric Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Sarcoma;   Mesothelioma;   Neuroendocrine Tumors;   Squamous Cell Cancer;   Merkel Cell Carcinoma;   Mismatch Repair Deficiency;   Microsatellite Instability
    Interventions:   Biological: Tumor Infiltrating Lymphocytes (TIL);   Drug: Fludarabine + Cyclophosphamide combination
    Sponsor:   Udai Kammula
    Recruiting

20. Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

21. Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

    Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

22. Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

    Condition:   Neoplasms
    Interventions:   Drug: Everolimus;   Drug: Sandostatin LAR Depot
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

23. Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity

    Condition:   Obesity
    Interventions:   Drug: Phentermine-Topiramate;   Dietary Supplement: Meal Replacement Therapy;   Other: Placebo
    Sponsor:   University of Minnesota
    Not yet recruiting

24. Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

    Conditions:   Advanced Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Multiple Endocrine Neoplasia Type 1;   Neuroendocrine Neoplasm;   Unresectable Carcinoid Tumor
    Interventions:   Drug: Everolimus;   Drug: Lenvatinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

25. [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma

    Condition:   Hepatocellular Carcinoma
    Intervention:   Diagnostic Test: [68Ga]DOTATATE-PET/MRI
    Sponsor:   University of Alabama at Birmingham
    Recruiting

26. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

27. Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

    Conditions:   Lung Non-Small Cell Squamous Carcinoma;   Minimally Invasive Lung Adenocarcinoma;   Neuroendocrine Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Large Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

28. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
    Recruiting

29. Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

    Conditions:   Carcinoma, Non-Small -Cell Lung;   Ovarian Neoplasms;   Small Cell Lung Carcinoma;   Uterine Cervical Neoplasms;   Carcinoma, Neuroendocrine;   Extrapulmonary Small Cell Cancer
    Interventions:   Drug: Topotecan;   Drug: VX-970 (M6620)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

30. A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

    Conditions:   Solid Tumor;   Medullary Thyroid Cancer
    Intervention:   Drug: Selpercatinib
    Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
    Not yet recruiting

31. A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

    Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting

32. Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

    Conditions:   Locally Advanced Adrenal Gland Pheochromocytoma;   Locally Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Metastatic Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Somatostatin Receptor Positive;   Stage III Thyroid Gland Medullary Carcinoma AJCC v8;   Stage IV Thyroid Gland Medullary Carcinoma AJCC v8;   Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8;   Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8;   Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Intervention:   Drug: Lutetium Lu 177 Dotatate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

33. Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

    Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Primary Malignant Central Nervous System Neoplasm;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Primary Malignant Central Nervous System Neoplasm;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

34. Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

    Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292 (selpercatinib)
    Sponsor:   Loxo Oncology, Inc.
    Recruiting

35. Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

    Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

36. Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer

    Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

37. A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

    Condition:   Metastatic Merkel Cell Carcinoma
    Intervention:   Drug: INCMGA00012
    Sponsor:   Incyte Corporation
    Recruiting

38. Adjuvant Avelumab in Merkel Cell Cancer

    Conditions:   Stage III Merkel Cell Carcinoma AJCC v8;   Stage IIIB Merkel Cell Carcinoma AJCC v8;   Stage IIIA Merkel Cell Carcinoma AJCC v8
    Interventions:   Drug: Avelumab;   Other: Peripheral Blood Collection;   Other: Placebo
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   EMD Serono
    Recruiting

39. Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

    Conditions:   Merkel Cell Carcinoma;   Skin Cancer
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Recruiting

40. Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

    Conditions:   Advanced Malignant Solid Neoplasm;   Carcinoma of Unknown Primary;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Germ Cell Tumor;   Metastatic Malignant Solid Neoplasm;   Metastatic Paraganglioma;   Metastatic Penile Carcinoma;   Metastatic Skin Squamous Cell Carcinoma;   Small Cell Carcinoma;   Stage III Adrenal Cortex Carcinoma AJCC v7;   Stage IV Adrenal Cortex Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma;   Unresectable Skin Squamous Cell Carcinoma;   Unresectable Solid Neoplasm;   Vascular Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

41. A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

    Conditions:   Cancer;   Neoplasms;   Metastatic Cancer;   Triple Negative Breast Cancer;   Gastric Cancer;   Cervical Cancer;   Ovarian Cancer;   Hepatocellular Carcinoma;   Squamous Cell Carcinoma of Head and Neck;   Urothelial Carcinoma;   Urothelial Neoplasm;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Locally Advanced Solid Tumor;   Locally Advanced Malignant Neoplasm;   Squamous Cell Carcinoma;   Sarcoma;   Merkel Cell Carcinoma;   Bladder Cancer
    Interventions:   Drug: OC-001;   Drug: OC-001 in Combination
    Sponsor:   Ocellaris Pharma, Inc.
    Not yet recruiting

42. the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma

    Condition:   Pheochromocytoma
    Interventions:   Drug: Dexmedetomidine;   Drug: General anesthetic
    Sponsor:   National Cancer Institute, Egypt
    Recruiting

43. A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

    Conditions:   Adrenocortical Carcinoma;   Pheochromocytoma;   Paraganglioma
    Intervention:   Biological: EO2401
    Sponsor:   Enterome
    Not yet recruiting